Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix. Ligand will pay ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments Mergers and Acquisitions

Ligand Pharma (LGND) Tops Q1 EPS by 30cMay 4, 2016 8:16 AM Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 MillionMay 4, 2016 5:59 AM